18 completed, 12 recruiting, 8 unknown, 2 terminated. 42 Phase 2, 7 Phase 3, 5 Phase 1.
Follow Speech Disorders: new trials by email Literature Review of Speech Disorders trials Research Report on Speech Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Superiority Trial of Aphasia-focused Rehabilitation With tDCS Stimulation tDCS - Aphasia, Broca's Aphasia | Phase 2 / Phase 3 | Recruiting | University of South Carolina | 130 | 2026-07-14 | 2026-07-21 |
| Lumateperone in the Treatment of Stuttering, Childhood Onset Fluency Disorder Lumateperone (ITI-007), Placebo Tablet or Capsule - Stuttering, Adult | Phase 2 | Recruiting | CSTrials Inc. | 24 | 2026-04-18 | 2026-07-29 |
| Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter Psilocybin, Speech therapy - Stuttering | Phase 2 | Not yet recruiting | NYU Langone Health | 25 | 2026-01-15 | 2025-12-22 |
| Exploratory Evaluation of the Digital Therapeutic Device Zenicom for Subacute Stroke Aphasia Zenicog, Conventional Speech Therapy - Aphasia, Stroke | Phase 2 | Recruiting | Seoul National University Bundang Hospital | 20 | 2025-12-10 | 2026-02-10 |
| Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia Neflamapimod, Placebo - Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | Phase 2 | Active not recruiting | EIP Pharma Inc | 20 | 2025-10-02 | 2026-07-06 |
| Comparing Traditional Semantic Feature Analysis (tSFA) and Semantic Feature Analysis + Metacognitive Strategy Training (SFA+MST) Semantic Feature Analysis (traditional), Semantic Feature Analysis + Metacognitive Strategy Training - Aphasia, Aphasia Following Cerebral Infarction | Phase 2 | Recruiting | Teachers College, Columbia University | 40 | 2025-07-28 | 2026-06-25 |
| Transcranial Magnetic Stimulation + Language Therapy to Treat Mild Aphasia Transcranial Magnetic Stimulation (TMS), Speech-Language Therapy (SLT) - Aphasia, Stroke | Phase 2 | Recruiting | University of Pennsylvania | 24 | 2025-02-11 | 2026-03-05 |
| Lateral Cord Magnetic Stimulation For Refractory Spastic Cerebral Palsy Magnetic Spinal Stimulation - Spastic Cerebral Palsy, Dysarthria | Phase 2 / Phase 3 | Unknown | Sociedad Argenttina de Neuromodulación | 20 | 2024-11-18 | 2023-11-21 |
| Communication Bridge 3 Study Communication Bridge™, Evidence-Based Impairment Focused - Primary Progressive Aphasia | Phase 2 | Recruiting | University of Chicago | 200 | 2024-08-23 | 2026-06-01 |
| Transcranial Magnetic Stimulation + Language Therapy to Treat Subacute Aphasia Transcranial Magnetic Stimulation (TMS), Modified Constraint Induced Language Therapy (mCILT) - Stroke, Aphasia | Phase 2 | Recruiting | University of Pennsylvania | 63 | 2024-08-01 | 2026-06-18 |
| Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia Active tDCS + Language Therapy, Sham tDCS + Language Therapy - Primary Progressive Aphasia, Logopenic Progressive Aphasia | Phase 2 | Recruiting | Johns Hopkins University | 180 | 2024-02-13 | 2026-05-05 |
| Adaptive Trial Scheduling in Naming Treatment for Aphasia Adaptive Spacing Condition, High-Item Non-Adaptive Spacing Condition, Low-Item Non-Adaptive Spacing Condition - Aphasia, Stroke | Phase 2 | Recruiting | University of Pittsburgh | 32 | 2023-12-06 | 2025-12-11 |
| Balancing Effortful and Errorless Learning in Naming Treatment for Aphasia Accuracy-maximized condition, Effort-maximized condition, Effort-accuracy balanced condition - Aphasia, Stroke | Phase 2 | Recruiting | University of Pittsburgh | 30 | 2023-11-27 | 2026-04-13 |
| A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) Intrathalamic AAV.PGRN administration, Intrathalamic AVB-101 - Frontotemporal Dementia, FTD | Phase 1 / Phase 2 | Recruiting | AviadoBio Ltd | 18 | 2023-08-30 | 2026-08-13 |
| Nabilone for Agitation in Frontotemporal Dementia Nabilone, Placebo - Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant | Phase 2 | Terminated | Simon Ducharme, MD | 3 | 2023-03-07 | 2026-07-28 |
| Remotely Supervised Transcranial Direct Current Stimulation (tDCS) for Primary Progressive Aphasia (PPA) Transcranial Direct Current Stimulation (tDCS), Word-Naming Activity - Primary Progressive Aphasia | Phase 2 | Completed | NYU Langone Health | 11 | 2022-12-24 | 2024-09-19 |
| Escitalopram and Language Intervention for Subacute Aphasia Escitalopram 10mg, Placebo, Computer-delivered naming treatment - Aphasia, Stroke | Phase 2 | Recruiting | Johns Hopkins University | 88 | 2021-07-18 | 2026-09-03 |
| Dopaminergic Therapy for Frontotemporal Dementia Patients Rotigotine 4Mg/24Hrs Patch, Rotigotine 6Mg/24Hrs Patch, Placebo - Frontotemporal Dementia, Dementia | Phase 2 | Completed | I.R.C.C.S. Fondazione Santa Lucia | 75 | 2021-06-03 | 2024-10-22 |
| Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely) Ecopipam, Placebo - Childhood-Onset Fluency Disorder (Stuttering) | Phase 2 | Completed | Emalex Biosciences Inc. | 68 | 2020-10-22 | 2026-09-23 |
| Speech Entrainment for Aphasia Recovery SET (Speech Entrainment Therapy) 3 weeks, SET (Speech Entrainment Therapy) 4.5 weeks, SET (Speech Entrainment Therapy) 6 weeks - Aphasia, Aphasia Non Fluent | Phase 2 | Completed | Medical University of South Carolina | 80 | 2020-08-21 | 2025-11-14 |
Showing 20 of 42. Sign in to see all of them.
Aphasia (24) · Stroke (14) · Aphasia, Primary Progressive (8) · Stuttering (7) · Communication Disorders (5) · Dementia (5) · Frontotemporal Dementia (5) · Aphasia, Broca (4) · Language (4) · Language Disorders (4) · Central Nervous System Diseases (3) · Communication (3) · Mutism (3) · Alzheimer Disease (2)
Pathological Conditions, Signs and Symptoms (42) · Signs and Symptoms (42) · Neurobehavioral Manifestations (41) · Neurologic Manifestations (41) · Nervous System Diseases (40) · Language Disorders (38) · Communication Disorders (37) · Brain Diseases (23) · Central Nervous System Diseases (22) · Mental Disorders (15) · Cardiovascular Diseases (14) · Cerebrovascular Disorders (14) · Vascular Diseases (13) · Neurodevelopmental Disorders (9)
Transcranial Direct Current Stimulation (5) · Speech Therapy (2) · Transcranial Magnetic Stimulation (2) · ecopipam (2) · Capsules (1) · Escitalopram (1) · Fluoxetine (1) · Language Therapy (1) · Methods (1) · Psilocybin (1) · SET protein, human (1) · Spermine Synthase (1) · Therapeutics (1) · Transcutaneous Electric Nerve Stimulation (1) · carbidopa, levodopa drug combination (1)
University of Pennsylvania (3) · Johns Hopkins University (2) · NYU Langone Health (2) · University of Pittsburgh (2) · University of South Carolina (2) · University of Sydney (2) · AviadoBio Ltd (1) · CSTrials Inc. (1) · Charité Neurocure AG Flöel (1) · EIP Pharma Inc (1) · Emalex Biosciences Inc. (1) · Endo USA Inc., a Keenova Therapeutics Company (1) · Gerald Maguire, MD (1) · H. Branch Coslett (1) · I.R.C.C.S. Fondazione Santa Lucia (1)
United States (29) · Canada (6) · Germany (3) · Australia (2) · Italy (2) · United Kingdom (2) · Argentina (1) · Belgium (1) · Netherlands (1) · Norway (1) · Poland (1) · Russia (1) · South Korea (1) · Spain (1) · Sweden (1)
H. Branch Coslett, MD (3) · William Evans, PhD (2) · Agnes Floeel, Prof MD (1) · Agnes Floel, MD (1) · Alessandro Martorana, MD, PhD (1) · Alexander A Ostanin, MD, PhD (1) · Argye Hillis-Trupe, MD (1) · Atul R Mahableshwarkar, MD, DFAPA (1) · Bruce Crosson, PhD (1) · Elena R Chernykh, MD, PhD (1) · Emily Roglaski, PhD (1) · Gayatri Devi, MD (1) · Gerald A Maguire, MD (1) · Giacomo Koch, MD (1) · Hanne Kristensen, MD, PhD (1)
PMID 10917410, PMID 12849360, PMID 15026214, PMID 15212606, PMID 15328899, PMID 20075648, PMID 21636820, PMID 24434529, PMID 25267381, PMID 28738099, PMID 29357099, PMID 30128538, PMID 31369655, PMID 32878377, PMID 33642973, PMID 33643204, PMID 34941929, PMID 40809903, PMID 42161555
R01DC019325 (2), 2023 (1), P50DC014664 (1), R01AG055425 (1), R01AG075111 (1), R01DC007387 (1), R01DC016800 (1), R21DC021833 (1), U01DC011739 (1), U01DC017521 (1), U01DC022447 (1)